Home > Consideration of the naphthylpyrovalerone analogues and related compounds.

Advisory Council on the Misuse of Drugs. [Home Office UK] (2010) Consideration of the naphthylpyrovalerone analogues and related compounds. London: Home Office. 24 p.

[img]
Preview
PDF (Naphyrone report) - Published Version
133kB

This report is a consideration of naphyrone (also known as NRG-1, Energy1, or O-2482; or naphthylpyrovalerone), a naphthyl analogue of pyrovalerone, which acts as a triple monoamine reuptake inhibitor, producing psychostimulant effects (hereafter referred to as naphyrone). Internationally, it is controlled under Schedule IV of the 1971 UN Conventions.


Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance, CNS stimulants
Intervention Type:AOD disorder harm reduction
Source:Home Office UK
Date:2010
Pages:24 p.
Publisher:Home Office
Corporate Creators:Advisory Council on the Misuse of Drugs
Place of Publication:London
EndNote:View
Accession Number:HRB (Electronic Only)
Related URLs:
Subjects:B Drugs and alcohol substances > CNS stimulants
L Social psychology and related concepts > Legal availability or accessibility
J Health care, prevention and rehabilitation > Health care administration > Health care quality control
B Drugs and alcohol substances > New (novel) psychoactive substances
VA Geographic area > Europe > United Kingdom
A Drugs and alcohol use, abuse, and dependence > Drugs and alcohol effects and consequences
MP-MR Policy, planning, economics, work and social services > Policy > Policy on drugs and alcohol > Harm reduction policy

Repository Staff Only: item control page